The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
-
- STATUS
- Not Recruiting
-
- participants needed
- 96
-
- sponsor
- Ridgeback Biotherapeutics, LP
Laura Szewczyk
Primary Contact
John Hopkins Hospital (7.7 mi away) Contact
+8 other locationSummary
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.
Description
Phase 2a randomized, placebo-controlled, double-blinded clinical trial of EIDD-2801 in adult men and women who have tested positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection within 144 hours of polymerase chain reaction (PCR) confirmation and are hospitalized with a diagnosis of COVID-19. Rapid enrollment and treatment will be initiated such that the first dose of EIDD-2801 or placebo will be administered as soon as possible and within 7 days of onset of symptoms.
Details
| Condition | SARS-CoV 2 |
|---|---|
| Treatment | Placebo, EIDD-2801, 200 mg EIDD-2801, 300 mg EIDD-2801, Placebo (PBO), Placebo (PB0) |
| Clinical Study Identifier | NCT04405739 |
| Sponsor | Ridgeback Biotherapeutics, LP |
| Last Modified on | 26 May 2022 |
Similar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer